Segment 1 — Overview Conclusion This quarter's results exceeded expectations, primarily due to strong growth in the Evernorth Specialty business and medical cost trends at Cigna Healthcare coming in lower than expected.

Segment 2 — Key Data Adjusted EPS reached $7.79, up 16% year-over-year; Evernorth revenue $58.4B (+9%); Cigna Healthcare medical loss ratio 79.8%, below guidance.

Segment 3 — Business Progress This quarter, Evernorth Specialty profit grew 20%, driven by high demand for biosimilars and specialty generics as well as contributions from the Shields investment. Cigna Healthcare earnings increased 18%, benefiting from low influenza visits and weather-related deferred visits. The company announced that it will exit the individual exchange business by year-end and initiated a strategic review of eviCore, focusing on core growth platforms. AI applications reduced Cigna Healthcare digital customer calls by 20% and PBS member calls by 25%. The new "Signature" rebate-free pharmacy model received positive market feedback, with plans to cover at least 50% of PBS members by 2028. Management transition: Brian Evanko will assume the role of CEO on July 1.

Segment 4 — Guidance and Outlook Full-year adjusted EPS guidance raised to at least $30.35. Q2 EPS is expected to account for approximately 25% of the full year, Cigna Healthcare's first-half profit share slightly above 60%, and Q2 MCR will be slightly above the full-year range.

Segment 5 — Risk/Highlight Signals Positive signals: Management demonstrated high confidence, raising full-year guidance and emphasizing AI and new business models driving long-term growth. Negative signals: The CFO clearly stated that "cost trends remain high with no expectation of near-term moderation," and the PBS business declined $150 million year-over-year due to client renewals and transformation investments.